Irst-Irccs

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Acute lymphoblastic leukaemia1 trial
• Diffuse large B-cell lymphoma1 trial
• Glioblastoma1 trial
• Neuroendocrine tumours1 trial
• Pancreatic cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 22 trials

Status

• Completed2 trials
• Recruiting2 trials
• Terminated1 trial

Lead sponsor

• Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS4 trials
• Istituto Oncologico Veneto IRCCS1 trial

Running trials

• Recruiting

  Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04300101· Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS· Source

  Contact: Gerardo Musuraca, MD

• Recruiting

  "Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL

  NCT06919393· Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS· Source

  Contact: Anna Ferrari, Dr

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute lymphoblastic leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting

Closed trials

• Completed

  Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

  NCT04810182· Istituto Oncologico Veneto IRCCS· Source

• Completed

  Experimental Study to Evaluate the Impact of 18 Fluoro-PSMA (18F-PSMA) PET / CT in the Management of Patients with Prostate Cancer.

  NCT04775602· Phase 2· Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS· Source

• Terminated

  Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors

  NCT02489604· Phase 2· Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS· Source